Forensic Analysis · Chemicals · as of Nov 10, 2026
Chemours Co (CC)
A forensic read on Chemours Co built from its complete SEC filings — financial-health screens, earnings quality, red flags and a price-aware rating. Reproducible math, not opinion.
F · Poor — capital at risk
Forensic grade
Grey Zone
Financial health
1.5
Distress distance
Clean
Earnings quality
4
Forensic signals
-94.0%
ROE
0.4%
Revenue growth
This free snapshot doesn't read filing or proxy text, so the auditor-quality and governance checks that can lower a grade were not evaluated (auditor quality, say on pay, board independence, going concern). Those checks only ever lower a grade, so the full analysis can land below the grade above but never above it — treat it as the most favourable reading, not the settled one.
Chemours Co earns an F (Poor — capital at risk) forensic quality grade, and its balance-sheet distress test reads 1.5, placing it in the Grey zone. 4 forensic signals were flagged in its latest SEC filings, led by return on invested capital.
What the filings flag
-0.1%
FY2025
Return on invested capital.Return on invested capital is -0.1% in the latest fiscal year, against -1.9% in FY2023, having run between -1.9% and 5.0% across FY2023–FY2025 with no direction held. After-tax operating profit was ($87M) in FY2023 and ($6M) in FY2025. The capital base behind it went from $4.6B in FY2023 to $5.0B in FY2025 (+10%), while the revenue it carried went from $6.1B to $5.8B. FY2023's operating profit carried a $97M asset write-down that alone took about 1.7 points off that year's return, so about 1.7 of the 1.8-point rise across FY2023–FY2025 is that charge leaving the base year rather than the capital earning more. FY2024's operating profit carried a $56M goodwill write-off and a $27M asset write-down that alone took about 1.1 points off that year's return; FY2024 sits between the two ends of FY2023–FY2025, so the charge shapes the path between them without moving the change across it. A non-cash write-down lowers the reported return in the year it lands.
$56M
FY2024
Goodwill impairments.Took $56M of goodwill writedowns across 1 year (FY2024 ($56M)) — about 81% of net income over the span. A large writedown means an acquisition turned out worth far less than was paid — a real mark against M&A discipline.
153% of FCF
FY2025
Shareholder returns.Returned $78M to shareholders (buybacks + dividends) in FY2025 — 153% of free cash flow, but 30% of operating cash flow. Returns run ahead of free cash flow, with the gap funded by debt or cash reserves rather than the cash the business itself throws off; the payout itself is still covered by operating cash. Counting the $21M of stock-based comp paid out in shares on top of that, the combined claim on free cash flow is 194%.
-47%
FY2024→FY2025
Dividend — cut.The payout was CUT ~47% in FY2025 (from FY2024). It still returns some cash, but it is NOT the dependable, rising dividend an unbroken streak implies.
Key fundamentals
Latest Revenue$5.81B
Revenue Growth YoY+0.4%
Revenue CAGR (2yr)-2.2%
Net Margin-6.6%
Free Cash Flow$51.0M
Return on Equity-94.0%
The forensic grade and screens above are free — no account needed. Want the AI investment read on top — the 0–100 rating, thesis, bull-vs-bear, red flags and the 12-month scenario, written from Chemours Co's actual 10-K/10-Q/8-K filings?